Untangling Breast Cancer: Trailing Towards Nanoformulations-based Drug Development

Area of Science:

• Oncology
• Nanomedicine
• Biotechnology

Background:

• Breast cancer (BC) is a significant global health concern, representing 15% of cancer mortality and posing treatment challenges, especially for metastatic forms.
• While nanotechnology has improved survival rates, metastatic BC remains difficult to treat, with a low overall survival rate.
• Understanding BC epidemiology, classification, risk factors, and treatment challenges is crucial for developing effective therapies.

Purpose of the Study:

• To review the role of nanotechnology-based nanoformulations in breast cancer (BC) treatment.
• To provide insights into novel nanoformulations for BC therapy and guide the design of new nanomedicines.
• To highlight potential research opportunities, clinical applications, and existing challenges of nanoformulations in BC.

Main Methods:

• Literature review focusing on nanotechnology applications in breast cancer treatment.
• Analysis of various nanoformulations, including liposomes, dendrimers, and polymeric nanomaterials.
• Examination of patented nanoformulations and clinical trial progression.

Main Results:

• Nanotechnology-based nanoformulations show potential in improving breast cancer treatment outcomes.
• Various nanoformulation types are being explored for tumor therapeutics.
• Artificial intelligence plays a role in advancing nanoformulation development and application.

Conclusions:

• Nanotechnology offers a promising avenue for overcoming challenges in breast cancer treatment, particularly for metastatic disease.
• Further research and development of nanoformulations are essential for effective tumor management and improved patient survival.
• Clinical translation of nanoformulations requires addressing current challenges and exploring innovative approaches, including AI-driven strategies.